We report on a 61-year-old man with elevated serum prostate-specific antigen level of 10.5 ng/mL who had undergone prior negative standard transrectal ultrasound biopsy at another institution. He was referred to our medical center for evaluation and underwent a clinical 3-T multiparametric MRI and a research protocol PET/CT with the cellular proliferation radiotracer 18 F-FMAU (2′-deoxy-2′-[ 18 F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil). The PET/CT and multiparametric MRI were fused with transrectal ultrasound images for real-time hybrid image-based targeting of the biopsy needle. PET/CT with 18 F-FMAU was helpful in localizing the nonstandard biopsy sites that on histopathology revealed suspected tumor deposits.
. Axial T2-weighted (T2, left column), diffusion-weighted imaging apparent diffusion coefficient map (ADC, mid column), and dynamic contrast-enhanced (DCE, right column) demonstrate a heterogeneous enlarged prostate gland (6.3 Â 4.4 Â 5.5 cm, apex to base, AP and transverse, respectively, with volume of 79.3 mL) with focal regions of T2 hypointensity, mildly decreased ADC, and mild hyperperfusion (enclosed in circles) at the bilateral bases of the peripheral zone, which were considered nonspecific in view of focal scar and chronic hematoma from prior biopsy procedure. . Three-dimensional biopsy mapping trajectories constructed from the fused 18 F-FAMU PET/CT, multiparametric MRI (mpMRI), and transrectal ultrasound images. The yellow spheres denote the locations of the PET and mpMRI abnormities within the gland represented in a volumetric matrix mesh denoting the prostate gland boundaries. Green and orange poles portray standard biopsy and PET/mpMRI directed biopsy sites, respectively. None of the standard biopsy sites revealed carcinoma. The left base targeted biopsy site (with focal 18 F-FMAU uptake) revealed atypical small acinar proliferation suspicious for early malignancy. Accurate prostate tumor localization and characterization allows for image-directed biopsy and focal therapy. 1 PET in conjunction with radiotracers that track the thymidine salvage pathway of DNA synthesis has been studied for noninvasive imaging-based assessment of cellular proliferation in cancer. 2 The radiolabeled thymidine analog 18 F-FMAU is preferentially phosphorylated by the mitochondrial thymidine kinase 2 and becomes incorporated into the DNA. 3 Normal biodistribution of 18 F-FMAU in human shows relatively high tracer uptake in the liver and the renal cortex; moderate uptake in the salivary glands, heart, and spleen; and relatively low uptake in the bone marrow. 2 We have previously shown that there may be an association between androgen signaling and thymidine metabolism and that 18 F-FMAU PET may be useful in prostate tumor characterization. 4 An automated cGMP-compliant radiosynthesis of 18 F-FMAU has also been described. 5, 6 Multimodal image-guided localization, characterization, and targeting of prostate tumors may alleviate the current overdiagnosis (and overtreatment) of indolent tumors and underdiagnosis (and loss of opportunity for delivery of appropriate treatment including focal therapy) of aggressive tumors. 7, 8 
